Quantitative Investment Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 88.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 9,355 shares of the medical research company's stock after selling 71,567 shares during the period. Quantitative Investment Management LLC's holdings in Amgen were worth $2,914,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its position in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Forum Financial Management LP boosted its stake in shares of Amgen by 0.7% during the 4th quarter. Forum Financial Management LP now owns 352,784 shares of the medical research company's stock worth $91,950,000 after buying an additional 2,411 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Amgen by 12.9% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 36,971 shares of the medical research company's stock valued at $9,636,000 after acquiring an additional 4,232 shares in the last quarter. Integrated Wealth Concepts LLC increased its position in shares of Amgen by 3.4% in the fourth quarter. Integrated Wealth Concepts LLC now owns 23,256 shares of the medical research company's stock valued at $6,061,000 after acquiring an additional 765 shares during the last quarter. Finally, Nebula Research & Development LLC bought a new position in shares of Amgen in the fourth quarter valued at $1,181,000. Institutional investors own 76.50% of the company's stock.
Insiders Place Their Bets
In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company's stock, valued at $2,141,000.91. This represents a 14.95% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.76% of the company's stock.
Amgen Price Performance
Shares of Amgen stock traded down $1.61 during trading on Wednesday, reaching $287.97. 1,400,593 shares of the company's stock were exchanged, compared to its average volume of 2,120,274. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $339.17. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm's 50-day moving average price is $293.28 and its 200 day moving average price is $293.08. The company has a market cap of $155.03 billion, a P/E ratio of 23.55, a PEG ratio of 2.49 and a beta of 0.49.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the firm posted $4.97 EPS. The firm's revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 annualized dividend and a dividend yield of 3.3%. Amgen's payout ratio is currently 77.84%.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on AMGN shares. Wall Street Zen cut Amgen from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Erste Group Bank downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Piper Sandler raised their target price on shares of Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a research note on Monday. Morgan Stanley upped their price target on shares of Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $305.00 price target on shares of Amgen in a report on Tuesday, June 24th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $304.43.
Check Out Our Latest Stock Report on AMGN
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
MarketBeat All Access